Last reviewed · How we verify
DC Vaccination for Postremission Therapy in AML
The aim of this study is to determine the feasibility and safety of an autologous DC immunotherapy in patients with AML of non-favorable risk profile.
Details
| Lead sponsor | Ludwig-Maximilians - University of Munich |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | COMPLETED |
| Enrolment | 13 |
| Start date | Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Sep 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Myeloid Leukemia
Interventions
- DC vaccination for postremission therapy in AML
Countries
Germany